To study the function of the Krüppel-like transcription factor KLF13 in vivo we generated mice with a disrupted Klf13 allele. Whilst Klf13 
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-cells indicating an increase in less mature erythroblasts. A higher proportion of the Ter119 med CD71 hi cells were proliferating indicating that the mice were under a degree of erythropoietic stress. These data indicate that KLF13 is involved in the normal control of erythropoiesis.
Erythrocytes differentiate from multipotential haematopoietic stem cells through a series of intermediates.
The first committed erythrocyte precursors are the burst forming unit cells (BFU-E) which differentiate into colony forming units (CFU-E) and then to proerythroblasts (1) . As these cells differentiate further through the b a s o p h i l i c , p o l y c h r o m a t i c a n d orthochromatic erythroblast stages the nucleus shrinks and is finally shed as the cells become reticulocytes before becoming erythrocytes (2) . During these later stages of differentiation the cells lose expression of CD71 and gain the expression of ter119 so that these cell surface markers can be used to differentiate the different cell stages (3) . The process of erythrocyte differentiation is controlled by a number of different transcription factors and regulated such that under normal conditions sufficient erythrocytes are produced predominantly by the bone marrow but under conditions of erythropoietic stress (e.g. hypoxia) the number of erythrocytes can be increased and this occurs predominantly in the spleen (4, 5) .
Analysis of the transcriptional program controlling erythroblast differentiation has identified a number of different transcription factors that are critical to the normal development of erythrocytes (1, 2, 6) . The best studied of these factors regulating erythroid differentiation is GATA-1 a zinc finger transcription factor initially identified as a protein that bound to the globin genes and activated their expression (7) . Loss of GATA-1 leads to a failure of erythropoiesis early in gestation resulting in death of the embryos from severe anaemia by E10.5 (8) .
The erythroblasts in these embryos fail to develop past a pro-erythroblast like stage.
Another transcription factor that has been studied extensively in erythrocytes is the Krüppel-like factor (KLF) EKLF/KLF1, a member of a family of at least 16 transcription factors (9, 10) . Members of this family can both activate and repress transcription through interaction with a range of different transcription factors (e.g. the GATA factors and NF-κB) and cofactors (e.g. p300, mSin3A) (11) (12) (13) (14) . KLF1 was first identified as a CACC box binding factor expressed in erythroleukaemia cells but not in monocytes/macrophages (15). Mice that lack expression of Klf1 die at E16 from a severe anaemia indicating a critical role for KLF1 in the formation of erythrocytes (16) . At least 8 other xKLF proteins (KLF2-5, 8 and 11-13) are expressed in erythroid cell lines. Of these KLF2, 5, 8 and 13 have been shown to bind to CACCC boxes in globin promoters and can modify promoter activity in transfection assays (17) . KLF2 null mice die before E14.5, from a defect in the formation of the endothelium but also have reduced expression of embryonic ε-globin although expression of adult globin genes is normal (18) . K L F 1 3 ( K L F 1 3 /BTEB3/FKLF2/RFLAT) is another xKLF protein expressed in the haematopoietic system (19, 20) . Binding of KLF13 activates the promoters of a number of erythroid genes including γ -globin, GATA-1, p o r p h o b i l i n o g e n d e a m i n a s e a n d ferrochelatase in vitro (21) . KLF13 is highly expressed in human peripheral blood lymphocytes and binds to and activates the RANTES promoter in late activated T cells (20, 22) . We showed that murine KLF13 was widely expressed during embryogenesis with high levels of expression in the developing heart, thymus and liver (19) .
We have generated mice with a targeted deletion of exon one of the Klf13 allele and found that these mice have enlarged hearts and an increased susceptibility to the formation of cardiac vacuolar lesions (Keramatipour et al. submitted). To determine the role of Klf13 in the differentiation of erythroid cells we have compared erythropoiesis in Klf13 -/-and Klf13 +/+-mice.
EXPERIMENTAL PROCEDURES Mice
Klf13-/-mice generated in the CCB (129S6Sv/Ev) ES cell line were maintained on this genetic background. Genotyping of tail DNA was performed by PCR using p r i m e r s C A G 3 F (GCCTCCGCTCGACGTCCCTAAGA) and CAG3R (GCGCGCTCTTCTCCGGCTG) For purification using magnetic beads, splenocytes were incubated on ice with biotin labelled anti Ter119 at 1µg/10 6 cells for 30 min before 50µl of streptavidin magnetic beads were added. After a further 10 min on ice the samples were placed against a magnet until the beads were against the side of the tube. Samples were washed by resuspension in PBS +2% FCS 3 times before being resuspended in 300µl of RLT buffer (Qiagen) for RNA purification.
Total RNA from sorted cells was extracted using RNAeasy (Qiagen, Valencia, CA). Reverse transcription and quantitative real-time PCR were performed as described previously (23) . Primer sequences are available on request. Klf13 transcript levels for each sample were normalised to rRNA levels which were amplified using TaqMan Universal PCR Master Mix (Applied Biosystems, Warrington, UK). BFU-E and CFU-E colony forming assays.
BFU-E and CFU-E cultures were performed using the methocult system (StemCell Technologies) according to manufacturer's instructions. In brief, BM and spleen cells were plated at a density of 2 x 10(5) cells per ml 1% methylcellulose medium containing 15% FBS, 1% BSA, 10ug/ml insulin, 200ug/ml transferrin and 3U/ l EPO C lt i b t d t 37 o C in 5% CO 2 . CFU-E were enumerated after 2 days in culture and BFU-E after 3-4 days in culture. All cultures were done in duplicate and each experiment repeated eight times.
Statistical Analysis Statistical analyses for differences between

Klf13
+/+ and Klf13 -/-mice were performed using the two tailed Student's t test assuming unequal variance. Data are presented as mean ± SD with n values given in the corresponding figure legends.
RESULTS
Generation of the Targeting Construct
A genomic clone containing the mouse Klf13 gene (PAC F69-B12) was obtained by screening the mouse genome filter set RCP121 with the full length (1200 bp) Klf13 coding sequence (Genbank accession No. AJ245644). In silico comparison of the Klf13 coding sequence w i t h t h e g e n o m i c s e q u e n c e (ENSMUSG00000052040) together with experimental verification by Southern analysis and PCR showed that the Klf13 gene consisted of two exons. Exon 1 codes for the transactivation domain and the first zinc finger of the protein and exon 2 codes for the other two zinc fingers. To identify the start of the first exon, the 5' end of the known coding sequence together with 200bp of presumed upstream sequence identified from the mouse htgs database was compared with the EST database using the BLAST algorithm. The majority of the EST sequences containing the 5' part of the Klf13 coding sequence stopped at one of two positions separated by 30 nucleotides indicating the presence of two transcriptional start sites (Fig. 1A) . The sequence upstream of the start sites did not contain a TATA box indicating that Klf13 has a TATA-less promoter. To generate a vector to delete the first exon of Klf13 a 1.5kb fragment (mouse chromosome 7, nucleotides 59688488 to 59689967) of the promoter region and 4.9 kb of the intron (chromosome 7, nucleotides 59682698 to 59687527) were amplified by PCR and cloned into the vector pKO-DTA along with a neomycin resistance cassette. All the fragments and the final targeting vector were sequenced to confirm the PCR fidelity and to result in a null allele. The resulting vector pDPN is shown in Fig. 1B .
To generate recombinant ES cells with a targeted mutation in Klf13, pDPN was linearised in the vector backbone with PvuII and electroporated into ES cells. Cells were selected in G418 and resistant clones were picked and expanded. DNA was extracted from 45 clones and amplified by PCR using primer PF and PR to identify clones with the appropriate 5' insertion of the DNA. This process identified 14 clones and DNA from these clones was digested with EcoRI and analysed by Southern blot. Probing the blot with a DNA probe to the 5kb intron gave a band >13kb for the wild-type locus and an 11kb band for the targeted locus (Fig. 1C) . Twelve out of 45 clones contained the targeted locus giving an overall targeting frequency of 27% of the clones picked. The targeted ES cells were injected into C57Bl/6 blastocyts to generate transgenic mice.
Klf13 null mice
Genotyping of the offspring of the mice was performed by PCR for both the wild type and mutant alleles as shown in Fig  1D. This analysis showed that whilst null mice were detected after weaning, the numbers were less than that predicted by Mendelian inheritance (Table 1) . To determine whether the lethality arose from an early embryonic loss, embryos from timed matings of Klf13 +/-females with Klf13 -/-males were examined and genotyped at E10.5 and E13.5. At neither of these time points was there any detectable deviation from Mendelian ratios (n=31 embryos at E=10.5 with 14 Klf13
-/-and 17 Klf13
+/-embryos; n= 59 embryos at E13.5 with 30 Klf13 +/-embryos and 29 Klf13 -/-embryos). The cause and time of onset of the lethality has yet to be determined. To confirm that the Klf13 -/-mice did not express KLF13 mRNA, RNA from the heart (a tissue which expresses high levels of KLF13) was reverse transcribed and amplified by PCR. KLF13 mRNA was not detectable by this method in Klf13 -/-mice ( Fig 1E) . Quantification of mRNA from the heterozygous animals suggested that these mice expressed approximately half of the mRNA levels expressed in wild-type mice (Fig 1F) . It is therefore likely that KLF13 does not l t it i
Altered blood cell composition in Klf13 -/-mice To determine the effect of loss of KLF13 on the haematopoietic system, blood samples were taken and complete blood counts determined. Whilst the haematocrit of Klf13 -/-mice was the same as wild type mice the numbers of red cells were reduced by 10% and their size (MCV) was increased (see Table 2 ). Consequently the blood of the Klf13 -/-mice was populated with fewer but larger red blood cells. Despite the altered erythrocyte profile, total haemoglobin levels in the Klf13 -/-mice were unaltered. Klf13
-/-mice also had reduced numbers of lymphocytes (to 70% of wild type) and a trend towards reduced numbers of granulocytes (to 76% of wild-type) and monocytes (to 77% of wild-type) suggesting that the loss of KLF13 affects the pathways involved in the differentiation or survival of the major blood cell types ( -/-and 3.73±0.6 mg/g body weight Klf13
+/+ , Fig, 2A ). Furthermore, there was a proportionate increase in the number of cells isolated from the spleens of Klf13 -/-mice compared to their K l f 1 3 + / + counterparts (Fig 2B) indicating that the increase in spleen size is due to an increase in cell number rather than fibrosis.
Flow cytometry using anti-CD3ε and anti-CD19 showed a reduction in the proportions of T and B cells in the spleens of Klf13 -/-mice (Fig 2C) which when adjusted for spleen cell number showed no difference in absolute lymphocyte number between Klf13 -/-and Klf1 +/+ mice. Consequently the proportion of cells that did not stain for CD3ε or CD19 increased from 10% in the wild type mice to 33% in the Klf13 -/-mice. These data indicate that the increased splenomegaly. Staining the cells for CD45 identified three cell populations CD45
- (Fig  2D) , CD45 med (Fig 2D upper left) and CD45 hi (Fig 2D upper right) . . Fig  3A (3) . These populations are represented in Figure 3B as I, II, III and IV respectively and can be further characterised by their size with an overall decrease in cell size from type I to Type IV. flow cytometric analysis (Fig. 3A) Erythropoiesis in the BM Whilst some erythropoiesis occurs in the spleen under normal conditions, most splenic erythropoiesis occurs as a response to haematologic stress (5). The process of normal erythropoiesis occurs mostly in the BM. Therefore to determine whether the same defects occurred in erythropoiesis in the BM we determined the proportion of type I to type IV cells in the BM. This analysis showed an increase in type II erythroblasts (p<0.03) in the BM and a trend to an increase in the number of type I cells but this did not reach significance (p=0.06). There was no effect on the other erythroblast populations (Fig. 3D) .
To analyse the ability of progenitors from Klf13 -/-mice to differentiate along the erythropoietic lineage we determined the number of BFU-Es and CFU-Es in the spleen. Consistent with the increase in Ter119 med CD71 hi cells both BFU-Es and CFU-Es were increased in the spleen ( Figs  3E and 3F ). In the BM there was no change in the number of CFU-E or BFU-E. Together with the CD71/Ter119 staining these data suggest that loss of KLF13 does not inhibit the commitment of cells to the erythrocyte lineage.
Expression of transcription factors involved in erythropoiesis
To determine whether the expression of other transcription factors known to be i l d i th diff ti ti f erythrocytes was altered by the lack of Klf13, we determined the expression of GATA-1, KLF1 and KLF3 by Q-RTPCR in Ter119 + cells isolated by magnetic bead separation from the spleens of Klf13 -/-and Klf13 +/+ mice. The mRNA for all of these transcription factors increased at least 3-fold in the erythroblasts of Klf13 -/-mice (Fig.  4A) . It is possible that the increase in the mRNA for these transcription factors was due to differences in the proportion of -/-mice. These data indicate that the cell proliferation increased in type I cells but not in more mature erythroblasts (Fig.  5A) .
Altered expression of apoptosis associated genes in KLF13 -/-mice The final stages of erythroid differentiation requires the expression of genes associated with apoptosis (2). Therefore, we determined the expression of the major determinants of apoptosis in Ter119 +ve cells by Q-RT-PCR. This analysis showed that there was no change in the expression of Bad or Bcl-2 and a trend towards an increase in the expression of Bax but this did not reach significance (Fig. 5B) . However there was a marked (4.5 fold) increase in the expression of Bcl-xL in the splenocytes from Klf13 -/-mice compared to their wild-type counterparts (Fig. 5B) -/-mice is likely to arise from the increase in proportion of immature cells in the spleens of these mice (Fig 5C) . Consistent with these observations we did not observe a significant reduction in apoptosis in Ter119 + cells by annexin staining. During the preparation of this paper Zhou et al (24) published their analysis of a similar line of KLF13 -/-mice. This analysis showed a marked reduction in apoptosis and increased expression of BclxL in thymocytes. Thus it appears that BclxL is a major target of KLF13 in thymocytes but not in erythrocytes.
DISCUSSION
Previous studies have implicated Klf13 in the differentiation of erythrocytes in vitro (17, 22) . Our data demonstrate a role for Klf13 in these cells in vivo by showing that there is an increase in the number of immature erythrocytes in the spleens of mice that lack expression of Klf13. Indeed the reduced levels of other cell types in the circulation of the Klf13 -/-mice suggest that Klf13 is required for the differentiation and/or proliferation of other haematopoietic cell lineages.
Our data indicate that the cells were able to commit to the erythrocyte lineage as there was no change in the number of BFUEs or CFU-Es in the bone marrow. However the cells accumulate in the proerythroblast stage of development and have increased expression of KLF3. Mice that lack KLF3 have also been shown to have splenomegaly although the mechanism behind this phenotype is unexplored raising the possibility that both KLF13 and KLF3 act at the same point but that the increase in KLF3 is insufficient to overcome the loss of KLF13. An alternative explanation of these data is that KLF13 is an inhibitor of Klf3 expression in erythroblasts.
Erythropoiesis is disrupted in several other lines of mice with targeted mutations to transcription factors. For example, both GATA-1 and KLF1 are required for erythropoiesis to occur mice (8, 16) . Mice with low levels of expression of GATA-1 survive but become increasingly anaemic with age (25) and show stress erythropoiesis as a compensation for defective primary erythropoiesis. This phenotype is similar to that seen in lyn -/-mice which have reduced expression of GATA-1 and KLF1 (26) . The splenomegaly observed in our mice is also consistent with a stress erythropoietic response. However, in our mice we found little change in the expression of both Klf1 and GATA-1 in Ter119 + cells in contrast to the data from lyn -/-mice. This difference suggests that Klf13 regulates a different stage of erythropoiesis to that regulated by KLF1 and GATA-1. Furthermore, it suggests that although KLF13 is known to bind to and activate the GATA-1 promoter it is not a major regulator of GATA-1 expression. However, it is also possible that KLF13 interacts with and/or cooperates with GATA-1 to drive a subset of GATA-1 functions in erythropoiesis. Such an interaction has recently been shown between GATA-4 and KLF13 in Xenopus and results in a failure of cardiac development and a reduction in the expression of B-type naturietic peptide in this model (27) . The extent of any requirement for KLF13 in the function of GATA-1 is also dependent on the ability of other KLF proteins to compensate for the loss of KLF13 in some but not all activities of GATA-1.
Apoptosis of erythrocytes occurs in the spleen as a feedback mechanism to regulate the number of erythrocytes and splenomegaly has been shown in mice with aberrant apoptosis (28, 29) . It was therefore possible that loss of Klf13 resulted in a reduction in apoptosis and consistent with this suggestion during the preparation of this paper Zhou et al (24) published their analysis of Klf13 -/-mice and showed that KLF13 was an inhibitor of the expression of the antiapoptotic factor Bcl-xL. However, in our mice there was no significant change in annexin staining in Ter119 + cells suggesting that there was no increase in apoptosis in these mice. Furthermore we found no detectable increase in Bcl-xL expression once the change in proportion of immature cells was accounted for. However, we did detect an increase in the expression of cyclin B in Ter119 + cells suggesting an increase in proliferation. Together these data suggest that increased proliferation rather than a reduction in apoptosis leads to the increase in spleen size.
In summary the data presented here identify a role for Klf13 in the maturation of erythrocytes. Loss of Klf13 results in an increase in the expression of Klf3 and cyclin B but other Klf13 target genes in erythroblasts remain to be identified. Spleens were taken from 7 week old female Klf13 -/-mice and their wild-type counterparts. The spleens were weighed and compared to the body weight of the mouse (n=26 of each genotype) (A ). Splenocyte suspensions were prepared as described in Materials and Methods and the cells counted on a haemocytometer (n=7 of each genotype) (B). Cell suspensions were stained with anti-CD19 and anti-CD3 and analysed by flow cytometry. There was a large increase in the percentage (3 fold, n = 12 mice) of unstained cells. Cell percentages from a representative experiment are shown (C). Cells were stained for CD45; CD45
-(bottom left hand area), CD45 med (box R2) and CD45 hi (box R3) (D). The cells in these areas were quantified and normalised to the average for wild-type mice (E) (n = 6 mice for each line). All data are mean ± SD, * p<0.02, **p<0.005, *** p<0.0001 wt vs Klf13 -/-).. -/-and wild-type mice identified four erythroblast populations (I to IV; values given are mean percentages corrected for spleen size). The overlay plots shows the CD71 fluorescence profile of populations II and III from a wild-type and klf13 -/-mouse. The four populations identified in (A) populations were quantified (B) and normalised to the average number in wild type mice (data are mean ± SD, n = 6 mice for each line). Clear bars represent wild-type and b1ack bars represent Klf13 -/-mice. C. Splenocytes from wild-type mice were stained with antibodies to ter119 and CD71 and sorted by FACS. A minimum of 10 5 cells were collected for each population and the RNA extracted. RNA was reverse transcribed and amplified in real-time PCR reactions using primers for Klf13. Klf13 mRNA was normalised to rRNA. D. Femoral bone marrow cells were stained with Ter119 and CD71 and separated by FACS. The four erythroblast populations were quantified and normalised to the average number in wild-type mice (n = 6 mice of each genotype). Splenocytes and bone marrow cells from wild type and Klf13 -/-mice were cultured in methylcellulose as described in Materials and Methods. Numbers of CFU-E colonies (E) and BFU-E colonies (F) on each plate were normalised to the average number of colonies on the plates from wild-type mice (n=8 for each line). All data are presented as mean ± SD, * p<0.03, **p<0.01 wt vs Klf13 
